Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism

Biochemistry
Michael J Volles, Peter T Lansbury

Abstract

Two mutations in the protein alpha-synuclein (A30P and A53T) are linked to an autosomal dominant form of Parkinson's disease. Both mutations accelerate the formation of prefibrillar oligomers (protofibrils) in vitro, but the mechanism by which they promote toxicity is unknown. Protofibrils of wild-type alpha-synuclein bind and permeabilize acidic phospholipid vesicles. This study examines the relative membrane permeabilizing activities of the wild type, mutant, and mouse variants of protofibrillar alpha-synuclein and the mechanism of membrane permeabilization. Protofibrillar A30P, A53T, and mouse variants were each found to have greater permeabilizing activities per mole than the wild-type protein. The leakage of vesicular contents induced by protofibrillar alpha-synuclein exhibits a strong preference for low-molecular mass molecules, suggesting a pore-like mechanism for permeabilization. Under conditions in which the vesicular membrane is less stable (lack of calcium as a phospholipid counterion), protofibril permeabilization is less size-selective and monomeric alpha-synuclein can permeabilize via a detergent-like mechanism. We conclude that the pathogenesis of Parkinson's disease may involve membrane permeabilization by prot...Continue Reading

Citations

Feb 11, 2005·The Journal of Membrane Biology·B L KaganR Azimova
Oct 30, 2007·Acta Neuropathologica·William J BurkeJames E Galvin
Jan 24, 2009·Apoptosis : an International Journal on Programmed Cell Death·Oren A LevyLloyd A Greene
Jul 27, 2007·Cell Biochemistry and Biophysics·Klaus Beyer
Aug 28, 2012·Molecular Neurobiology·Stephan N Witt
Jun 25, 2009·Neurotoxicity Research·Leslie CrewsEliezer Masliah
Oct 3, 2003·Trends in Neurosciences·Kevin Welch, Junying Yuan
Jun 20, 2003·Neuropharmacology·Kumlesh K DevHerman van der Putten
Jul 10, 2003·Lancet Neurology·John HardyAndrew Singleton
May 25, 2012·Biochemistry·Irina SurguchevaAndrei Surguchov
Feb 18, 2009·Biochemistry·Adam J Trexler, Elizabeth Rhoades
Oct 8, 2011·Journal of the American Chemical Society·Nicholas P ReynoldsStefan Seeger
Feb 23, 2012·Journal of the American Chemical Society·Gemma ComellasChad M Rienstra
Mar 17, 2010·The Journal of Physical Chemistry. B·Candace M Pfefferkorn, Jennifer C Lee
Jul 19, 2002·Nature·Hilal A LashuelPeter T Lansbury
Feb 4, 2011·Metallomics : Integrated Biometal Science·Heather R Lucas, Jennifer C Lee
Nov 15, 2011·Integrative Biology : Quantitative Biosciences From Nano to Macro·Michael R SierksShalini Prasad
Feb 9, 2011·Proceedings of the National Academy of Sciences of the United States of America·Lise GiehmBente Vestergaard
Oct 19, 2011·Proceedings of the National Academy of Sciences of the United States of America·Wei WangQuyen Q Hoang
Feb 23, 2013·Proceedings of the National Academy of Sciences of the United States of America·Bong-Kyu ChoiYeon-Kyun Shin
Nov 7, 2012·The Journal of Biological Chemistry·Katharina FlachMax Holzer
Apr 26, 2008·The Journal of Biological Chemistry·Julie E TetzlaffPamela J McLean
Jan 24, 2009·The Journal of Biological Chemistry·Motokuni YonetaniMasato Hasegawa
Feb 27, 2009·Antioxidants & Redox Signaling·Jeanne M M TanKah-Leong Lim
Sep 6, 2008·Human Molecular Genetics·Jun LiangStephan N Witt
Apr 24, 2010·Human Molecular Genetics·Leslie Crews, Eliezer Masliah
Apr 23, 2008·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·Yoshikuni MizunoHideki Mochizuki
Feb 23, 2012·Cold Spring Harbor Perspectives in Medicine·Leonidas Stefanis
Jun 22, 2002·BMJ : British Medical Journal·Lawrence I Golbe
Jun 15, 2005·Annual Review of Biochemistry·Mark R Cookson
Oct 19, 2006·Journal of Biomedicine & Biotechnology·Atsushi TakedaKatsutoshi Furukawa
Jul 26, 2011·The Journal of Clinical Investigation·David S GoldsteinYehonatan Sharabi
Feb 6, 2009·Molecular Neurodegeneration·Mark R Cookson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alpha-Synuclein Aggregation (MDS)

Alpha-synucleins are small proteins that are believed to restrict the mobility of synpatic vesicles and inhibit neurotransmitter release. Aggregation of these proteins have been linked to several types of neurodegenerative diseases including dementia with Lewy bodies and Parkinson's disease. Here is the latest research on α-synuclein aggregation.